Functional Genetic Polymorphisms in the Aromatase Gene CYP19A1 Vary the Response of Postmenopausal Women with Primary Breast Cancer to Neoadjuvant Therapy with Aromatase Inhibitors.

Trial Profile

Functional Genetic Polymorphisms in the Aromatase Gene CYP19A1 Vary the Response of Postmenopausal Women with Primary Breast Cancer to Neoadjuvant Therapy with Aromatase Inhibitors.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs Letrozole (Primary)
  • Indications Early breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 29 Jul 2014 Status changed from not yet recruiting to completed as reported by Chinese Clinical Trial Register record
    • 21 May 2012 Planned end date (Jun 2023) added as reported by Chinese Clinical Trial Register record.
    • 20 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top